Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
New England Journal of Medicine · 13.08.2026 · 395 (7) · 671-683
DOI: 10.1056/nejmoa2604657 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.08.2026. Verfasst von Roberto Mina und 58 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Molecular Biotechnology and Health Sciences, Azienda Ospedaliero-Universitaria Città della Salute e della, Scie…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, Azienda Ospedaliero-Universitaria Città della Salute e della, Scienza di Torino, University of Turin, Turin, Italy.
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta.
- Istinye University, Ankara University, Ankara, Turkey.
- Cancer Center Clínica Universidad de Navarra, Cima, Pamplona, Spain.
- Beijing Chaoyang Hospital, Capital Medical University, Chaoyang District, Beijing.
- Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), Ce…
ORCID-Profile: Rahul Banerjee, Aurore Perrot
Förderung
- Johnson & Johnson
Zitieren
APA
Mina, R., Beksac, M., Rodríguez-Otero, P., Chen, W., Mateos, M. V., Li, J., Moreau, P., Cohen, Y. C., Min, C. K., Jelinek, T., Ye, J. C., Magen, H., Rubinstein, S. M., Fu, W., Hungria, V., Cengiz Seval, G., Farias, J. S., Radocha, J., Maral, S., …, & MonumenTAL-3 Investigators (2026). Talquetamab–Daratumumab in Relapsed or Refractory Myeloma. New England Journal of Medicine, 395(7), 671-683. https://doi.org/10.1056/nejmoa2604657
Vancouver
Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV, Li J, et al. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma. New England Journal of Medicine. 2026;395(7):671-683. doi:10.1056/nejmoa2604657
BibTeX
@article{Mina2026,
author = {Mina, Roberto and Beksac, Meral and Rodríguez-Otero, Paula and Chen, Wenming and Mateos, María-Victoria and Li, Jian and Moreau, Philippe and Cohen, Yael C and Min, Chang-Ki and Jelinek, Tomas and Ye, Jing Christine and Magen, Hila and Rubinstein, Samuel M and Fu, Weijun and Hungria, Vania and Cengiz Seval, Guldane and Farias, Joao Samuel and Radocha, Jakub and Maral, Senem and Turgut, Mehmet and Koh, Youngil and O'Leary, Daniel and Schmidt Filho, Jayr and Thertulien, Raymond and An, Gang and Huang, Shang-Yi and Grosicki, Sebastian and Tyczyńska, Agata and Banerjee, Rahul and Pianko, Matthew J and Martínez-López, Joaquín and Steckiewicz, Pawel and Maruyama, Dai and Fukushima, Kentaro and Oriol, Albert and Lopez Pardo, Jordi and Goldschmidt, Hartmut and Pawlyn, Charlotte and Perrot, Aurore and Zamagni, Elena and Dimopoulos, Meletios A and Rasche, Leo and Tolbert, Jaszianne and Terry, William and Courtoux, Christelle and Liu, Xiao and Vasey, Sandra Y and Connors, Kaitlyn and Festa, Mariacristina and Heuck, Christoph and Langlois, Angélique and O'Rourke, Lisa and Zhou, Jiangxiu and Qin, Xiang and Lu, Jiashen and Gong, Joy and Vieyra, Diego and Voorhees, Peter M and MonumenTAL-3 Investigators, MonumenTAL-3 Investigators},
title = {Talquetamab–Daratumumab in Relapsed or Refractory Myeloma},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {7},
pages = {671--683},
doi = {10.1056/nejmoa2604657}
}
EUVIMED